{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:21:35Z","timestamp":1792606895022,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP2 CA196335"],"award-info":[{"award-number":["DP2 CA196335"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["TRAN1-08533"],"award-info":[{"award-number":["TRAN1-08533"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001558","name":"Concern Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.trecan.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:18:02Z","timestamp":1630451882000},"page":"1059-1073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Engineering stem cells for cancer immunotherapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2021.08.004_bb0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: Harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2021.08.004_bb0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2021.08.004_bb0020","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2021.08.004_bb0030","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/cancers12092567","article-title":"The landscape of car-t cell clinical trials against solid tumors\u2014a comprehensive overview","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2021.08.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0040","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.86","article-title":"Toward 'off-the-shelf' allogeneic CAR T cells","volume":"3","author":"Aftab","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.trecan.2021.08.004_bb0060","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2021.08.004_bb0065","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0070","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2021.08.004_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2021.08.004_bb0080","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2021.08.004_bb0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4049\/jimmunol.161.1.375","article-title":"Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains","volume":"161","author":"Roberts","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0095","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.hoc.2017.06.012","article-title":"Hematopoietic stem cell approaches to cancer","volume":"31","author":"Adair","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.trecan.2021.08.004_bb0100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.trecan.2021.08.004_bb0110","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0115","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1201219","article-title":"Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment","volume":"333","author":"Notta","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.trecan.2021.08.004_bb0120","doi-asserted-by":"crossref","first-page":"982","DOI":"10.4161\/hv.27637","article-title":"Gene-modified hematopoietic stem cells for cancer immunotherapy","volume":"10","author":"Larson","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.trecan.2021.08.004_bb0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4939-8938-6_3","article-title":"Generation of antigen-specific T cells from human induced pluripotent stem cells","volume":"1899","author":"Nishimura","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular adjuvant properties, direct cytotoxicity of re-differentiated V\u03b124 invariant NKT-like cells from human induced pluripotent stem cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.trecan.2021.08.004_bb0145","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","article-title":"Generation of 'off-the-shelf' natural killer cells from peripheral blood cell-derived induced pluripotent stem cells","volume":"9","author":"Zeng","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.trecan.2021.08.004_bb0150","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.bbmt.2012.09.021","article-title":"Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells","volume":"19","author":"Kohn","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trecan.2021.08.004_bb0155","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1073\/pnas.0500600102","article-title":"Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells","volume":"102","author":"Yang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2021.08.004_bb0160","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1073\/pnas.092154599","article-title":"Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAS in hematopoietic precursor cells","volume":"99","author":"Yang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2021.08.004_bb0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances antitumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2021.08.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.trecan.2021.08.004_bb0175","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2021.08.004_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0185","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long terminal repeat CRISPR-CAR-coupled 'universal' T cells mediate potent antileukemic effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2021.08.004_bb0190","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.trecan.2021.08.004_bb0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2021.08.004_bb0200","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.gene.2013.03.098","article-title":"Gene therapy for PIDs: progress, pitfalls, and prospects","volume":"525","author":"Mukherjee","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.trecan.2021.08.004_bb0205","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood-2006-04-015230","article-title":"The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies","volume":"109","author":"Traversari","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0210","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","article-title":"Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation","volume":"107","author":"Berger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0215","first-page":"1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"376","author":"Bonini","year":"1997","journal-title":"Clin. Trial Sci."},{"key":"10.1016\/j.trecan.2021.08.004_bb0220","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0225","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood.V97.5.1249.h8001249_1249_1257","article-title":"A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease","volume":"97","author":"Thomis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0230","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0235","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/mt.2013.8","article-title":"Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem\/progenitor cells","volume":"21","author":"Giannoni","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2021.08.004_bb0240","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1084\/jem.184.6.2261","article-title":"Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice","volume":"184","author":"Hege","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0245","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bmt.1703119","article-title":"The role of bone marrow transplantation in acute promyelocytic leukemia","volume":"28","author":"Nabhan","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trecan.2021.08.004_bb0250","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.soncn.2009.03.006","article-title":"Non-myeloablative hematopoietic stem cell transplantation","volume":"25","author":"Shelburne","year":"2009","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.trecan.2021.08.004_bb0255","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-04-0117","article-title":"Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant","volume":"10","author":"Nieto","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2021.08.004_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(02)00092-0","article-title":"Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia","volume":"29","author":"Popat","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2021.08.004_bb0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/bbmt.2002.v8.pm12064365","article-title":"Autologous stem cell transplantation for small cell lung cancer","volume":"8","author":"Rizzo","year":"2002","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trecan.2021.08.004_bb0270","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/sj.bmt.1705472","article-title":"Phase I\/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer","volume":"38","author":"Frickhofen","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trecan.2021.08.004_bb0275","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/blood.V96.9.3001","article-title":"Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer","volume":"96","author":"McNiece","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0280","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1586\/14737140.5.5.835","article-title":"Autologous hematopoietic stem cell transplantation for pediatric solid tumors","volume":"5","author":"Hale","year":"2005","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.trecan.2021.08.004_bb0285","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611710","article-title":"How to combine the two landmark treatment methods\u2014allogeneic hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy together to cure high-risk B cell acute lymphoblastic leukemia?","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01342","article-title":"Graft engineering and adoptive immunotherapy: New approaches to promote immune tolerance after hematopoietic stem cell transplantation","volume":"10","author":"Bertaina","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0300","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41409-020-0982-6","article-title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells","volume":"56","author":"Gu","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trecan.2021.08.004_bb0305","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0310","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2021.08.004_bb0315","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0320","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0325","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-016-0357-z","article-title":"Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia","volume":"9","author":"Cai","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0330","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920927605","article-title":"Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL","volume":"12","author":"Yu","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0335","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CJI.0000000000000233","article-title":"Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: case report and review of the literature","volume":"41","author":"Zhang","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.trecan.2021.08.004_bb0340","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3324\/haematol.2019.233882","article-title":"Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: optimizing \u03b1\u03b2 T cell-depleted haploidentical hematopoietic stem cell transplantation","volume":"106","author":"Wiebking","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.trecan.2021.08.004_bb0345","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.4049\/jimmunol.178.10.6242","article-title":"Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation","volume":"178","author":"Pillai","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0350","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","article-title":"Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Chaidos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0355","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0360","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics, and antileukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0365","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.trecan.2021.08.004_bb0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/cas.13892","article-title":"Toward the development of true 'off-the-shelf' synthetic T-cell immunotherapy","volume":"110","author":"Iriguchi","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.trecan.2021.08.004_bb0375","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.4049\/jimmunol.0803670","article-title":"Generation of T cells from human embryonic stem cell-derived hematopoietic zones","volume":"182","author":"Timmermans","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0380","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.stem.2013.03.001","article-title":"Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation","volume":"12","author":"Wakao","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0385","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0390","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","article-title":"Roles of NKT cells in cancer immunotherapy","volume":"42","author":"Bae","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.trecan.2021.08.004_bb0395","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0400","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0405","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2021.08.004_bb0410","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/leu.2016.281","article-title":"Pre-transplant donor CD4 - invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease","volume":"31","author":"Rubio","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2021.08.004_bb0415","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1073\/pnas.1424877112","article-title":"Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells","volume":"112","author":"Smith","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2021.08.004_bb0420","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10875-012-9697-9","article-title":"Accumulation of activated invariant natural killer T cells in the tumor microenvironment after \u03b1-galactosylceramide-pulsed antigen presenting cells","volume":"32","author":"Nagato","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0425","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3389\/fimmu.2013.00409","article-title":"NKT cells as an ideal antitumor immunotherapeutic","volume":"4","author":"Fujii","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0430","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2021.08.004_bb0435","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"\u03b3\u03b4T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0440","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0445","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3389\/fimmu.2017.01031","article-title":"Shared and distinct phenotypes and functions of human cD161++ V\u03b17.2+ T cell subsets","volume":"8","author":"Kurioka","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0450","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","article-title":"The biology and functional importance of MAIT cells","volume":"20","author":"Godfrey","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0455","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature11605","article-title":"MR1 presents microbial vitamin B metabolites to MAIT cells","volume":"491","author":"Kjer-Nielsen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2021.08.004_bb0460","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/s41598-018-22130-1","article-title":"Enumeration, functional responses, and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma","volume":"8","author":"Gherardin","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2021.08.004_bb0465","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbmt.2017.10.003","article-title":"Graft-derived reconstitution of mucosal-associated invariant T cells after allogeneic hematopoietic cell transplantation","volume":"24","author":"Bhattacharyya","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trecan.2021.08.004_bb0470","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12185-018-2442-2","article-title":"Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation","volume":"108","author":"Kawaguchi","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0475","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2159-8290.CD-19-0569","article-title":"MAIT cells promote tumor initiation, growth, and metastases via tumor MR1","volume":"10","author":"Yan","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2021.08.004_bb0480","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical applications of gamma delta T cells with multivalent immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0485","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0490","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0495","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0500","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2021.08.004_bb0505","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0510","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fimmu.2020.00060","article-title":"Targeting natural killer cells for tumor immunotherapy","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0515","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/imt-2019-0139","article-title":"Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy","volume":"12","author":"Zhao","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.trecan.2021.08.004_bb0520","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0525","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2021.08.004_bb0530","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1017701","article-title":"Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer","volume":"4","author":"Cany","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2021.08.004_bb0535","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0540","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.4049\/jimmunol.175.8.5095","article-title":"Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity","volume":"175","author":"Woll","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0545","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance antitumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0550","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0555","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00281-018-0721-x","article-title":"Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells","volume":"41","author":"Saetersmoen","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0560","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.V99.2.399","article-title":"Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem\/progenitor cells","volume":"99","author":"Cui","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0565","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1182\/blood-2002-04-1063","article-title":"Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF\/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses","volume":"100","author":"Weigel","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0570","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood.V99.5.1676","article-title":"In vivo manipulation of dendritic cells to induce therapeutic immunity","volume":"99","author":"Merad","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0575","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.stem.2018.12.011","article-title":"Organoid-induced differentiation of conventional T cells from human pluripotent stem cells","volume":"24","author":"Montel-Hagen","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2021.08.004_bb0580","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4049\/jimmunol.1202591","article-title":"Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell\u2013derived T cells","volume":"192","author":"St\u00e4rck","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0585","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/mt.2013.28","article-title":"Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression","volume":"21","author":"Vatakis","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2021.08.004_bb0590","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.8016643","article-title":"Regulation of MHC class II expression by interferon-\u03b3 mediated by the transactivator gene CIITA","volume":"265","author":"Steimle","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.trecan.2021.08.004_bb0595","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2021.08.004_bb0600","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0605","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/nm1431","article-title":"Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1","volume":"12","author":"Melkus","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0610","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2005-11-4388","article-title":"Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus\/liver and CD34+ cell transplantation","volume":"108","author":"Lan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2021.08.004_bb0615","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pone.0008208","article-title":"Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice","volume":"4","author":"Kitchen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2021.08.004_bb0620","doi-asserted-by":"crossref","first-page":"E1408","DOI":"10.1073\/pnas.1115050108","article-title":"Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells","volume":"108","author":"Vatakis","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2021.08.004_bb0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044664","article-title":"Graft versus host disease in the bone marrow, liver, and thymus humanized mouse model","volume":"7","author":"Greenblatt","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2021.08.004_bb0630","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1074-7613(02)00474-0","article-title":"Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro","volume":"17","author":"Schmitt","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2021.08.004_bb0635","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.immuni.2006.05.010","article-title":"Stage-specific and differential Notch dependency at the \u03b1\u03b2 and \u03b3\u03b4 T lineage bifurcation","volume":"25","author":"Ciofani","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2021.08.004_bb0640","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ni1234","article-title":"Notch promotes survival of pre-T cells at the \u03b2-selection checkpoint by regulating cellular metabolism","volume":"6","author":"Ciofani","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0645","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1084\/jem.20061442","article-title":"Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation","volume":"204","author":"Besseyrias","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2021.08.004_bb0650","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.smim.2007.10.005","article-title":"Generation of pro-T cells in vitro: potential for immune reconstitution","volume":"19","author":"Awong","year":"2007","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.trecan.2021.08.004_bb0655","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.4237","article-title":"Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids","volume":"14","author":"Seet","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.trecan.2021.08.004_bb0660","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm.2080","article-title":"Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution","volume":"16","author":"Delaney","year":"2010","journal-title":"Nat. Med."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803321001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803321001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:53:56Z","timestamp":1762505636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803321001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":132,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2405803321001710"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2021.08.004","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering stem cells for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}